DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 03:15:53 2024-06-10 pm EDT | ||
| 1.02 EUR | +8.51% |
|
| Current month | +15.91% | ||
| 1 month | +52.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 1.02 | +8.51% |
| 24-06-07 | 0.94 | +3.30% |
| 24-06-06 | 0.91 | 0.00% |
| 24-06-05 | 0.91 | -9.90% |
| 24-06-04 | 1.01 | +5.21% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 03:15 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7F |
| ISIN | DE000MG0D7F7 |
| Date issued | 2024-03-18 |
| Strike | 325 $ |
| Maturity | 2025-03-21 (284 Days) |
| Parity | 10 : 1 |
| Emission price | 0.86 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.36 € |
|---|---|
| Lowest since issue | 0.62 € |
| Spread | 0.06 € |
| Spread % | 5.45% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
254.9
USD
Average target price
363.9
USD
Spread / Average Target
+42.76%
- Stock Market
- Certificates
- Certificat
